Drug Profile
QPI 1007
Alternative Names: QPI-1007; siCASP2Latest Information Update: 22 Mar 2022
Price :
$50
*
At a glance
- Originator Quark Pharmaceuticals
- Class Antiglaucomas; Eye disorder therapies; Neuroprotectants; Small interfering RNA
- Mechanism of Action Caspase 2 expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Angle-closure glaucoma; Optic nerve disorders
Most Recent Events
- 22 Mar 2022 No development reported - Phase-II for Angle-closure glaucoma in USA, USA, Vietnam, Singapore (Intravitreous)
- 22 Mar 2022 No development reported - Phase-II/III for Optic nerve disorders in Singapore, China, Italy, Australia, Israel, India, USA, Germany (Intravitreous)
- 01 Jul 2019 Quark Pharmaceuticals terminates a phase II/III trial in Optic nerve disorders in USA, Canada, Singapore, Germany, Israel, India, Australia, Italy and China as an interim analysis did not warrant to continue the enrolment , (NCT02341560)